Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for 301015.SZ and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for 301015.SZ and 80,000+ other tickers.
See exactly how 301015.SZ's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 301015.SZ and 80,000+ other tickers.
Qingdao Baheal Medical Inc., established in 2005 and headquartered in Qingdao, China, operates as a pharmaceutical company. The firm's activities encompass the entire spectrum of drug development, from initial research to manufacturing and sales of various medicinal products. A key offering in its portfolio is vitamin D calcium in chewable tablet form.
No recent news available.